MicroTech Medical (Hangzhou) Co., Ltd. Class H (HK:2235)
:2235
Want to see HK:2235 full AI Analyst Report?
Top Page
MicroTech Medical (Hangzhou) Co., Ltd. Class H
(2235)
Select Model
Select Model
Rating:59Neutral
Price Target:
HK$8.00
▲(12.68% Upside)
Action:Reiterated
Date:05/07/26
The score is driven primarily by strong financial progress (surging revenue, stable gross margins, and a very low-debt balance sheet). This is tempered by still-developing cash flow and incomplete operating profitability, while technicals show overbought conditions and valuation is stretched due to the high P/E.
Positive Factors
Revenue Growth
Sustained, rapid revenue growth (101.1% in 2025) signals expanding product adoption and market share in diabetes care. Durable demand for pumps and follow-on consumables should lengthen revenue visibility, enabling scale benefits and supporting long-term investment in R&D and distribution.
Negative Factors
Negative Free Cash Flow
Despite improving operating cash flow, persistently negative free cash flow (~-6.1M in 2025) reflects ongoing investment or working capital needs. If sustained, this can constrain organic reinvestment, delay self-funded expansion, or require external financing to support growth initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained, rapid revenue growth (101.1% in 2025) signals expanding product adoption and market share in diabetes care. Durable demand for pumps and follow-on consumables should lengthen revenue visibility, enabling scale benefits and supporting long-term investment in R&D and distribution.
Read all positive factors
MicroTech Medical (Hangzhou) Co., Ltd. Class H (2235) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.39B
Dividend YieldN/A
Average Volume (3M)340.61K
Price to Earnings (P/E)71.2
Beta (1Y)0.34
Revenue Growth91.69%
EPS GrowthN/A
CountryHK
Employees678
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.11
Shares Outstanding169,175,840
10 Day Avg. Volume114,320
30 Day Avg. Volume340,611
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)1.42
Price to Sales (P/S)4.33
P/FCF Ratio-468.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$11.63Price Target Upside63.85% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.21
Revenue Forecast (FY)HK$902.75M
MicroTech Medical (Hangzhou) Co., Ltd. Class H Business Overview & Revenue Model
Company Description
MicroTech Medical (Hangzhou) Co., Ltd. engages in the research and development, manufacture, and commercialization of diabetes management medical devices and consumables in the People's Republic of China and internationally. Its products include E...
How the Company Makes Money
The company primarily makes money by selling diabetes medical devices and the recurring consumables tied to those devices. Key revenue streams typically include: (1) upfront sales of insulin pump systems (the durable hardware), generally recognize...
MicroTech Medical (Hangzhou) Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
84
Very Positive
Cash Flow
52
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 660.79M | 345.62M | 248.35M | 173.54M | 151.40M |
| Gross Profit | 357.42M | 182.85M | 123.22M | 79.66M | 70.88M |
| EBITDA | 29.02M | -121.38M | -184.12M | -110.19M | -39.80M |
| Net Income | 40.15M | -63.12M | -125.02M | -35.04M | -48.18M |
Balance Sheet | |||||
| Total Assets | 2.31B | 2.15B | 2.16B | 2.29B | 2.33B |
| Cash, Cash Equivalents and Short-Term Investments | 1.55B | 1.71B | 1.89B | 2.05B | 2.15B |
| Total Debt | 91.37M | 4.20M | 5.06M | 717.00K | 255.00K |
| Total Liabilities | 287.07M | 171.72M | 97.70M | 82.06M | 82.48M |
| Stockholders Equity | 2.02B | 1.97B | 2.06B | 2.21B | 2.25B |
Cash Flow | |||||
| Free Cash Flow | -6.11M | -203.88M | -181.69M | -137.45M | -62.94M |
| Operating Cash Flow | 31.80M | -120.65M | -153.00M | -107.67M | -44.22M |
| Investing Cash Flow | -351.63M | 121.16M | -540.70M | -965.58M | 97.69M |
| Financing Cash Flow | 55.22M | -33.15M | -23.46M | -20.57M | 1.57B |
MicroTech Medical (Hangzhou) Co., Ltd. Class H Technical Analysis
Positive
7.10
Price Trends
7.56
Positive
7.55
Positive
7.47
Positive
Market Momentum
0.10
Positive
57.80
Neutral
75.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2235, the sentiment is Positive. The current price of 7.1 is below the 20-day moving average (MA) of 7.92, below the 50-day MA of 7.56, and below the 200-day MA of 7.47, indicating a bullish trend. The MACD of 0.10 indicates Positive momentum. The RSI at 57.80 is Neutral, neither overbought nor oversold. The STOCH value of 75.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2235.
MicroTech Medical (Hangzhou) Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | HK$5.28B | 15.53 | 10.38% | 1.50% | 3.83% | -27.04% | |
59 Neutral | HK$3.39B | 71.23 | 2.04% | ― | 91.69% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | HK$582.14M | -2.30 | -21.29% | ― | -34.96% | 42.74% | |
42 Neutral | HK$2.43B | -1.03 | -6.63% | ― | -4.38% | ― |
* Healthcare Sector Average
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
8.00
1.82
29.45%
DE:4WO
Peijia Medical Ltd.
0.55
-0.09
-14.84%
DE:7W3
Acotec Scientific Holdings Limited
1.04
0.13
13.66%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.89
-2.26
-54.46%
HK:2172
MicroPort NeuroTech Limited
8.87
-1.09
-10.94%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.40
-1.18
-45.74%
MicroTech Medical (Hangzhou) Co., Ltd. Class H Corporate Events
MicroTech Medical Swings to Profit on Surging CGMS Demand in 2025
Mar 30, 2026
MicroTech Medical reported a sharp turnaround in 2025, driven by surging demand for its continuous glucose monitoring systems in China and abroad. The company’s operating revenue nearly doubled to RMB660.79 million, with CGMS sales rising 15...
MicroTech Medical Sets March 30 Board Meeting to Approve 2025 Annual Results
Mar 18, 2026
MicroTech Medical (Hangzhou) Co., Ltd., a Hong Kong-listed medical technology company, has a board that includes executive, non-executive and independent non-executive directors, led by chairman Zheng Pan. This structure underpins its compliance w...
MicroTech Medical Forecasts Strong 2025 Growth and Returns to Profit
Feb 26, 2026
MicroTech Medical has issued a positive profit alert for 2025, projecting revenue of at least RMB650 million, up about 88 percent year on year, and a turnaround to a net profit of no less than RMB38 million from a loss in 2024. The improvement is ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.